Hedge Fund Kahn Brothers’ Stock Picks for 2013: The New York Times Company (NYT) and More

The New York Times Company – Moving into the Digital AgeHedge funds and other major investors continue to file their 13Fs for the fourth quarter of 2012 this week, disclosing many of their long equity positions as of the end of December. We believe that there are multiple ways to take advantage of this information. One technique we use is to pool 13F filings in our database and use them to formulate investment strategies; the most popular small cap stocks among hedge funds as of the end of June 2012, as listed in our August newsletter, beat the S&P 500 index by 18 percentage points between September and January despite the significant delay from when these positions were actually held (read more about our hedge fund investing strategies).

Of course, investors can also treat individual 13F filings as a list of recommended stocks to be researched further if a quick look shows that they may be good values. Kahn Brothers, a fund Irving and Thomas Kahn have managed since 1978, recently filed its 13F. Read on for our thoughts on the fund’s five largest holdings and compare them to previous filings.

Kahn Brothers owned 2.5 million shares of Pfizer Inc. (NYSE:PFE) , making the pharmaceutical company its largest holding by market value. Pfizer was also billionaire Ken Fisher of Fisher Asset Management’s top stock pick for 2013 (see more of Fisher’s stock picks). The stock currently trades at 14 times trailing earnings, though revenue did decline last quarter compared to the fourth quarter of 2011. Analyst expectations imply a forward P/E of 12. Pfizer also pays a dividend yield of 3.6% at current divided levels, so it offers at least something of a combination of value and income.

Another of the fund’s top picks was Citigroup Inc. (NYSE:C) , with Kahn Brothers reporting a position of 1.3 million shares. Citi had been one of the ten most popular stocks among hedge funds in the third quarter of 2012, and there is a value case to be made given the substantial discount to book value (the P/B ratio is 0.7) and the forward P/E of 8. However, we think that peers offer considerably better stability and trailing earnings performance at a slight premium in asset-based terms; JPMorgan Chase & Co. (NYSE:JPM), for example, has a trailing P/E of 9 and a P/B of slightly less than 1.

New York Community Bancorp, Inc. (NYSE:NYCB) was another of Kahn Brothers’ favorite stocks. It is a $6 billion market cap bank holding company offering an attractive dividend yield. It is also valued at about the book value of its equity and at 12 times trailing earnings, so while not a screaming buy in value terms we would not be calling it overvalued either. With the business seeing slight growth it may be a good prospect for income investors.

Merck & Co., Inc. (NYSE:MRK) joined Pfizer as a pharmaceutical stock in the fund’s portfolio. The 1.1 million shares which Kahn Brother owned was roughly even with its stake from three months earlier. As a pharmaceutical company it’s unsurprising that Merck has a relatively low correlation with the broader market at a beta of 0.4 as well as a fairly high dividend yield. Point State Capital, managed by Sean Cullinan and other portfolio managers from Duquesne Capital, owned 6.5 million shares of Pfizer at the end of the third quarter.

Kahn Brothers slightly increased its holdings of The New York Times Company (NYSE:NYT) to a total of 4.8 million shares. The fund was the largest holder of the stock in our database of 13F filings, as many hedge funds shy away from the newspaper business. Revenue was down 10% in the fourth quarter of 2012 versus a year earlier, and Wall Street analysts expect the decline to continue. Even so, the forward earnings multiple is a fairly high 18. 11% of the outstanding shares are held short.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.The article Hedge Fund Kahn Brothers’ Stock Picks for 2013 originally appeared on Fool.com and is written by Jake Mann.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!